Suda Pharmaceuticals Ltd (SUD:ASX)

5.2¢

right-arrow Created with Sketch. 0 (0%)
MCAP $25.00M
Last trade 15.35pm 17/09/2021 20mins delayed

Latest Announcements

15/09/2021SUDSuda Pharmaceuticals Ltd
07/09/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
03/09/2021SUDSuda Pharmaceuticals Ltd
31/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
26/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
24/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
23/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
3,160
MCap
16/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd

Company Overview

SUDA Pharmaceuticals Limited is a biotechnology company focused on developing therapies to treat human disease. The Company is focused on two areas which include oncology and conditions that impact the central nervous system. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company’s OroMist technology develop oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

SUD in the news

SUDA Pharmaceuticals (SUD) appoints Reuben Benjamin to its scientific advisory board for…
SUDA Pharmaceuticals (SUD) enters an exclusive licence and distribution agreement with STADA…
Suda Pharmaceuticals (SUD) receives firm commitments to undertake a $3.65 million capital…
SUDA Pharmaceuticals (SUD) licenses an invariant Natural Killer T (iNKT) cell therapy…

Search Previous Announcements